دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Models for Evidence Generation During the COVID-19 Pandemic: New Opportunities for Clinical Trials in Cardiovascular Medicine.
Lawler, Patrick R. MD, MPH
doi : 10.1161/CIRCULATIONAHA.122.061231
Volume 147(3) pgs. 187-279,e32-e63 January 17, 2023
Social and Psychosocial Determinants of Racial and Ethnic Differences in Cardiovascular Health in the United States Population.
Shah, Nilay S. MD, MPH; Huang, Xiaoning PhD; Petito, Lucia C. PhD; Bancks, Michael P. PhD, MPH; Ning, Hongyan MD, MS; Cameron, Natalie A. MD; Kershaw, Kiarri N. PhD; Kandula, Namratha R. MD, MPH; Carnethon, Mercedes R. PhD; Lloyd-Jones, Donald M. MD, ScM; Khan, Sadiya S. MD, MSc
doi : 10.1161/CIRCULATIONAHA.122.061991
Social and psychosocial factors are associated with cardiovascular health (CVH). Our objective was to examine the contributions of individual-level social and psychosocial factors to racial and ethnic differences in population CVH in the NHANES (National Health and Nutrition Examination Surveys) 2011 to 2018, to inform strategies to mitigate CVH inequities.
Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
Martens, Pieter MD, PhD; Dauw, Jeroen MD; Verbrugge, Frederik H. MD, PhD; Nijst, Petra MD, PhD; Meekers, Evelyne MD; Augusto, Silvio Nunes Jr BSc; Ter Maaten, Jozine M. MD, PhD; Damman, Kevin MD, PhD; Mebazaa, Alexandre MD, PhD; Filippatos, Gerasimos MD, PhD; Ruschitzka, Frank MD; Tang, W.H. Wilson MD; Dupont, Matthias MD; Mullens, Wilfried MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.062486
Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
Wu, Hongyi MD ,*; Xu, Lili MD ,*; Zhao, Xin MD ,*; Zhang, Huanyi MB; Cheng, Kang MD; Wang, Xiaoyan MD; Chen, Manhua MB; Li, Guangping MD; Huang, Jiangnan MD; Lan, Jun MM; Wei, Guanghe MM; Zhang, Chi MD; Wang, Yinman MD; Qian, Juying MD; Ge, Junbo MD; on behalf of the OPTION Investigators
doi : 10.1161/CIRCULATIONAHA.122.062762
Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice.
Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.
Tani, Hidenori MD ,*; Sadahiro, Taketaro MD, PhD ,*; Yamada, Yu MD; Isomi, Mari BVSc; Yamakawa, Hiroyuki MD, PhD; Fujita, Ryo PhD; Abe, Yuto MD; Akiyama, Tatsuya MD; Nakano, Koji MD; Kuze, Yuta; Seki, Masahide PhD; Suzuki, Yutaka PhD; Fujisawa, Manabu MD, PhD; Sakata-Yanagimoto, Mamiko MD, PhD; Chiba, Shigeru MD, PhD; Fukuda, Keiichi MD, PhD; Ieda, Masaki MD, PhD
doi : 10.1161/CIRCULATIONAHA.121.058655
Because adult cardiomyocytes have little regenerative capacity, resident cardiac fibroblasts (CFs) synthesize extracellular matrix after myocardial infarction (MI) to form fibrosis, leading to cardiac dysfunction and heart failure.
Cardiac Reprogramming: Toward a Total Eclipse of the Failing Heart.
Garry, Glynnis A. MD; Olson, Eric N. PhD
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models.
Lee, Richard G. PhD; Mazzola, Anne Marie MS; Braun, Maurine C. MS; Platt, Colin PhD; Vafai, Scott B. MD; Kathiresan, Sekar MD; Rohde, Ellen PhD; Bellinger, Andrew M. MD, PhD; Khera, Amit V. MD, MSc
doi : 10.1161/CIRCULATIONAHA.122.062132
VERVE-101 is an investigational in vivo CRISPR base-editing medicine designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic protein production, and thereby durably lower low-density lipoprotein cholesterol.
A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities.
Beatty, Alexis L. MD, MAS; Beckie, Theresa M. PhD; Dodson, John MD; Goldstein, Carly M. PhD; Hughes, Joel W. PhD; Kraus, William E. MD; Martin, Seth S. MD, MHS; Olson, Thomas P. PhD, MS; Pack, Quinn R. MD, MSc; Stolp, Haley MPH; Thomas, Randal J. MD, MS; Wu, Wen-Chih MD; Franklin, Barry A.
doi : 10.1161/CIRCULATIONAHA.122.061046
AB Cardiac rehabilitation (CR) is a guideline-recommended, multidisciplinary program of exercise training, risk factor management, and psychosocial counseling for people with cardiovascular disease (CVD) that is beneficial but underused and with substantial disparities in referral, access, and participation.
ECG Challenge: AV Block or Something Else?.
Haghighat, Leila MD, MPhil; Goldschlager, Nora MD; Oesterle, Adam MD
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
Chen, Sha MD ,*; Wang, Qian MD ,*; Christodoulou, Andriana BSc ,*; Mylonas, Nikolaos BSc; Bakker, Diane BSc; Nederlof, Rianne PhD; Hollmann, Markus W. MD, PhD; Weber, Nina C. PhD; Coronel, Ruben MD, PhD; Wakker, Vincent BSc; Christoffels, Vincent M. PhD; Andreadou, Ioanna PhD ,+; Zuurbier, Coert J. PhD ,+
Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association.
Damluji, Abdulla A. MD, PhD, FAHA, Chair; Forman, Daniel E. MD, FAHA, Vice Chair; Wang, Tracy Y. MD, MHS, MSc, FAHA; Chikwe, Joanna MD, FAHA; Kunadian, Vijay MBBS, MD; Rich, Michael W. MD; Young, Bessie A. MD, MPH; Page, Robert L. II PharmD, MSPH, FAHA; DeVon, Holli A. PhD, RN, FAHA; Alexander, Karen P. MD, FAHA; on behalf of the American Heart Association Cardiovascular Disease in Older Populations Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Lifestyle and Cardiometabolic Health
doi : 10.1161/CIR.0000000000001112
AB Diagnostic and therapeutic advances during the past decades have substantially improved health outcomes for patients with acute coronary syndrome. Both age-related physiological changes and accumulated cardiovascular risk factors increase the susceptibility to acute coronary syndrome over a lifetime.
Correction to: A Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve.
